The DOI matches its Crossref record; 44 of the 46 references it cites were found in a registry or an index.
Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
Open accessAbstract
Background & aims Agents that induce an immune response against tumors by altering T-cell regulation have increased survival times of patients with advanced-stage tumors, such as melanoma or lung cancer. We aimed to characterize molecular features of immune cells that infiltrate hepatocellular carcinomas (HCCs) to determine whether these types of agents might be effective against liver tumors.Methods We analyzed HCC samples from 956 patients. We separated gene expression profiles from tumor, stromal, and immune cells using a non-negative matrix factorization algorithm. We then analyzed the gene expression pattern of inflammatory cells in HCC tumor samples. We correlated expression patterns with the presence of immune cell infiltrates and immune regulatory molecules, determined by pathology and immunohistochemical analyses, in a training set of 228 HCC samples. We validated the correlation in a validation set of 728 tumor samples. Using data from 190 tumors in the Cancer Genome Atlas, we correlated immune cell gene expression profiles with numbers of chromosomal aberrations (based on single-nucleotide polymorphism array) and mutations (exome sequence data).Results We found approximately 25% of HCCs to have markers of an inflammatory response, with high expression levels of the CD274 molecule (programmed death-ligand 1) and programmed cell death 1, markers of cytolytic activity, and fewer chromosomal aberrations. We called this group of tumors the Immune class. It contained 2 subtypes, characterized by markers of an adaptive T-cell response or exhausted immune response. The exhausted immune response subclass expressed many genes regulated by transforming growth factor beta 1 that mediate immunosuppression. We did not observe any differences in numbers of mutations or expression of tumor antigens between the immune-specific class and other HCCs.Conclusions In an analysis of HCC samples from 956 patients, we found almost 25% to express markers of an inflammatory response. We identified 2 subclasses, characterized by adaptive or exhausted immune responses. These findings indicate that some HCCs might be susceptible to therapeutic agents designed to block the regulatory pathways in T cells, such as programmed death-ligand 1, programmed cell death 1, or transforming growth factor beta 1 inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Inflamed tumours constitute ~30% of HCCs and exhibit extensive immune cell infiltration and immune activity, detected as increased expression of immune checkpoints (such as PD-1 or its ligand PD-L1), activation of IFN signalling and a low burden of large chromosomal alterations70,71,78.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [71]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, a high TMB does not correlate with increased immune infiltration70,71.”
From Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma (2024) · cites this paper as [71]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Murray, C. J. L., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J. A., Abdalla, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61689-4 · Cited by 8,888
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Cited by
Sorted by citations
Items 601–700 of 1,000
Hepatocellular Carcinoma: Optimal Radiological Evaluation before Liver Transplantation
Burgio, M. D., Garzelli, L., Cannella, R., Ronot, M., & Vilgrain, V. (2023) · Life · doi:10.3390/life13122267 · Cited by 7
Zhao, Y. C., Zhang, L., Zhang, Y., Meng, B., Ying, W., & Qian, X. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9560-7 · Cited by 7
Immune gene signature delineates a subclass of thyroid cancer with unfavorable clinical outcomes
Zhi, J., Yi, J., Tian, M., Wang, H., Kang, N., Zheng, X., & Gao, M. (2020) · Aging · doi:10.18632/aging.102963 · Cited by 7
Understanding the Immunoenvironment of Primary Liver Cancer: A Histopathology Perspective
Chung, A.-C., Nasralla, D., & Quaglia, A. (2022) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s382310 · Cited by 8
Progress towards molecular patient stratification of hepatocellular carcinoma: Lost in translation?
Chiang, D. Y., & Villanueva, A. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.031 · Cited by 7
Self-citationHermán‐Sánchez, N., del Río-Moreno, M., Ciria, R., Sánchez‐Frías, M., Fernández‐Barrena, M. G., Uriarte, I., Chicano‐Gálvez, E., Ortea, I., Peralbo‐Molina, Á., Briceño, J., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02206-5 · Cited by 6
Seraphin, T. P., Mesropian, A., Žigutytė, L., Brooks, J. A., Mauro, E., Gris‐Oliver, A., Pinyol, R., Montironi, C., Balaseviciute, U., Piqué‐Gili, M., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101592 · Cited by 6
Self-citationLei, M. M. L., Leung, C. O. N., Leung, R. W. H., Wu, X., Chung, K. P. S., Gu, C. Y. J., Chan, M. S. M., Chau, W. K., Mu, Q. H., Ng, K. Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-64860-7 · Cited by 6
Wang, X.-Y., Yan, B.-B., Yang, J.-H., Cheng, Z., Song, W.-C., Yang, Y.-F., & Wang, J.-H. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07574-0 · Cited by 6
Li, C., Jia, Y., Li, N., Zhou, Q., Liu, R., & Wang, Q. (2023) · Aging · doi:10.18632/aging.204899 · Cited by 6
Diao, L., He, M., Xu, B., Chen, L., Wang, Z., Yang, Y., Xia, S., Hu, S., Guo, S., & Li, D. (2023) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2023.100686 · Cited by 6
Shi, A., Yan, M., Pang, B., Pang, L., Wang, Y., Lan, Y., Zhang, X., Xu, J., Ping, Y., & Hu, J. R. (2023) · BMC Immunology · doi:10.1186/s12865-023-00587-8 · Cited by 6
Liu, Y., Zheng, Y., Zhao, X., Dong, Z., Zhang, M., Fang, Y., Wang, Y., Wang, Z., Liu, N., Yan, P., et al. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123474 · Cited by 7
The quest for precision oncology with immune checkpoint inhibitors for hepatocellular carcinoma
Cabibbo, G., & Singal, A. G. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.021 · Cited by 6
Kuwano, A., Tanaka, K., Yada, M., Nagasawa, S., Morita, Y., Masumoto, A., & Motomura, K. (2021) · Molecular and Clinical Oncology · doi:10.3892/mco.2021.2486 · Cited by 6
Peng, Y., Wu, G., Qiu, X. Y., Luo, Y., Zou, Y., Wei, X., & Li, A. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.916024 · Cited by 6
DNA Damage Repair Classifier Defines Distinct Groups in Hepatocellular Carcinoma
Smith, M. A., Alsten, S. C. V., Walens, A., Damrauer, J. S., Maduekwe, U. N., Broaddus, R. R., Love, M. I., Troester, M. A., & Hoadley, K. A. (2022) · Cancers · doi:10.3390/cancers14174282 · Cited by 6
Can MRI features predict clinically relevant hepatocellular carcinoma genetic subtypes?
Liu, X., Guo, Y., Zhao, L., Misdraji, J., Kapur, T., Abrams, T. A., & Shyn, P. B. (2023) · Abdominal Radiology · doi:10.1007/s00261-023-03876-3 · Cited by 6
Li, S., Zhu, Z., Lu, J. N., Cao, W., Song, F., Xiao, C., Zhang, P., He, Z., Weng, J., & Xu, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1159126 · Cited by 6
Li, B., Chen, L., Lu, S.-L., Lei, B., Yu, G.-L., & Yu, S. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i1.61 · Cited by 6
Computational methods in tumor immunology
Bhinder, B., & Elemento, O. (2020) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2020.01.001 · Cited by 6
Zheng, X., Li, L., Yu, C., Yang, J., Zhao, Y., Su, C., Yu, J., & Xu, M. (2021) · Aging · doi:10.18632/aging.203682 · Cited by 6
Tanaka, S. (2018) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12059 · Cited by 5
Krug, S., Mattheis, L., Haemmerle, M., Rosendahl, J., Kleeff, J. H., & Michl, P. (2021) · Cancer Reports · doi:10.1002/cnr2.1493 · Cited by 6
Lee, S. K., Lim, J., Jhun, J. Y., Moon, J., Kim, H. S., Choi, J. Y., Choi, H. J., You, Y. K., Han, J. W., Sung, P. S., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101518 · Cited by 5
Kirthika, P., Jawalagatti, V., Li, P., Xu, M. Y., Carceles‐Cordon, M., Ertel, A., Quinn, S. A., Petrylak, D. P., Orme, J. J., Dehm, S. M., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0629 · Cited by 5
Taniai, T., Haruki, K., Väyrynen, J. P., Gomisawa, K., Sato, S., Furukawa, K., Tsunematsu, M., Yanagaki, M., Shirai, Y., & Ikegami, T. (2025) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2025.110381 · Cited by 5
Balsano, R., Pino, M., Bocchero, E., Valenzi, E., Pressiani, T., Bozzarelli, S., & Rimassa, L. (2025) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2025.2557625 · Cited by 5
Sivapathasundaram, A., Golse, N., Pascale, A., Durand, E., Sebagh, M., & Besson, F. L. (2023) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000004574 · Cited by 5
Boilève, J., Guimas, V., David, A., Bailly, C., & Touchefeu, Y. (2024) · Current Oncology · doi:10.3390/curroncol31060242 · Cited by 6
Cowzer, D., Chou, J. F., Walch, H. S., Keane, F., Khalil, D. N., Shia, J., Do, R. K. G., Yarmohammadi, H., Erinjeri, J. P., Dika, I. E., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae110 · Cited by 5
Immunomodulatory role of vitamin D and emerging immunotherapies in hepatocellular carcinoma
Chiriva‐Internati, M., Grizzi, F., Monari, M., Taverna, G., Figueroa, J. A., Daoyan, W., & Bresalier, R. S. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1611829 · Cited by 6
Bertuzzi, C., Germinario, G., Righi, S., Ravaioli, M., Agostinelli, C., Pession, A., D’Errico, A., Sabattini, E., & Vasuri, F. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154016 · Cited by 5
Li, R., Chen, J., Zhao, W., Liang, R., & Xiong, H. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02540-2 · Cited by 5
Clinical value of identifying genes that inhibit hepatocellular carcinomas
Testa, U., Pelosi, E., & Castelli, G. (2022) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2022.2154658 · Cited by 5
Barsch, M., Salié, H., Mesesan, A., & Bengsch, B. (2023) · Liver Cancer International · doi:10.1002/lci2.72 · Cited by 5
Ma, R., Liu, W., Sun, T., Dang, C., & Li, K. (2023) · PeerJ · doi:10.7717/peerj.15373 · Cited by 5
Trial watch: immunotherapeutic strategies on the horizon for hepatocellular carcinoma
Koh, B., Tan, D. J. H., Lim, W. H., Wong, J. S. L., Ng, C. H., Chan, K. E., Wang, M., Yong, W. P., Dan, Y. Y., Wang, L. Z., et al. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2214478 · Cited by 6
SERPINB3 in fibrogenic chronic liver diseases and primary liver cancers
Pontisso, P., & Parola, M. (2024) · Exploration of Digestive Diseases · doi:10.37349/edd.2024.00038 · Cited by 5
Battista, D. D., Yakymi, R., Scheibe, E., Sato, S., Gerstein, H., Markowitz, T. E., Lack, J., Mereu, R., Manieli, C., Zamboni, F., et al. (2024) · Cancers · doi:10.3390/cancers16071370 · Cited by 5
Nishida, N. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0739 · Cited by 5
The histopathological and molecular heterogeneity of hepatocellular carcinoma: a narrative review
Chung, W., & Kim, H. (2024) · Ewha Medical Journal · doi:10.12771/emj.2024.e58 · Cited by 5
Zhang, L., Bluth, M. H., & Bhalla, A. (2018) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2018.03.003 · Cited by 5
Chen, W., Bi, K., Zhang, X., Jiang, J., & Diao, H. (2020) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2020.100067 · Cited by 5
Niger, M., Nichetti, F., Dell'Angelo, F., Cappelletti, V., Pircher, C., Vismara, M., Cotsoglou, C., Bhoori, S., Vingiani, A., Bartolomeo, M. D., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00472 · Cited by 5
Self-citationZhu, L., & Guo, W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.708819 · Cited by 5
Adisa, R. A., & Sulaimon, L. A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.105473 · Cited by 6
Systemic treatment of hepatocellular carcinoma: the times they are a-changin’
Campani, C., & Nault, J. (2021) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-21-412 · Cited by 5
Choi, H., Na, K. J., Jung, Y., Lim, M., Lee, D., Lee, J. E., Im, H., Lee, D., Koh, J., & Kim, Y. T. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.16.594592 · Cited by 5
Kanzaki, H., Ishino, T., Ogasawara, S., Tsuchiya, T., Fujiya, M., Sawada, M., Izai, R., Akatsuka, T., Miwa, C., Yonemoto, T., et al. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101614 · Cited by 4
Jin, Z., Fang, K., Zhang, X., Song, M., Jiang, H., & Liu, Y. (2025) · Human Mutation · doi:10.1155/humu/9967779 · Cited by 4
Wu, R., Gao, Y., Zhao, X., Guo, S., Zhou, H., Zhang, Y., Hou, Y., Lan, M., Zhi, H., Wang, P., et al. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107593 · Cited by 4
Human GM-CSF/IL-3 enhance tumor immune infiltration in humanized HCC patient-derived xenografts
Weinfurtner, K. M., Tischfield, D. J., McClung, G., Brain, J. A., Gordan, J. D., Jiao, J., Furth, E. E., Li, W., Supan, E. T., Nadolski, G., et al. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101264 · Cited by 4
Tumor aneuploidy as a prognostic and predictive biomarker in immune checkpoint blockade
Huang, D., Spurr, L. F., Weichselbaum, R. R., & Pitroda, S. P. (2025) · Nature Genetics · doi:10.1038/s41588-025-02226-x · Cited by 4
Ozaki, K., & Goshima, S. (2025) · Abdominal Radiology · doi:10.1007/s00261-025-05169-3 · Cited by 4
Intratumoral SPP1+BCL2A1+ Tumor-Associated Macrophages Predict Poor Response to PD1 Blockade
Lai, C.-H., Hung, Y.-P., Tseng, P., Satria, R. D., & Lin, C. (2025) · Diagnostics · doi:10.3390/diagnostics15212680 · Cited by 4
Hepatozelluläres Karzinom: neue multimodale Therapiekonzepte
Schultheiß, M., Bettinger, D., Fichtner‐Feigl, S., & Thimme, R. (2018) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0043-124158 · Cited by 5
Huang, J., Zhang, S., Yang, Y., Zhang, Z.-C., Jiang, N., Li, W.-C., Shen, J., Zhong, B., & Zhu, X. (2022) · Clinical Medicine Insights Oncology · doi:10.1177/11795549221134832 · Cited by 4
Aoki, T., Nishida, N., Minami, Y., & Kudo, M. (2024) · Liver Cancer · doi:10.1159/000541077 · Cited by 4
Lee, H. W., Park, S., Park, H. J., Cho, K. J., Kim, D. Y., Hwang, B., & Park, J. Y. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010958 · Cited by 4
Llamoza-Torres, C. J., Fuentes-Pardo, M., & Ramos‐Molina, B. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.64 · Cited by 6
Heikenwälder, M. F., & Pikarsky, E. (2017) · Seminars in liver disease (Print) · doi:10.1055/s-0037-1606255 · Cited by 4
The Impact of Translational Research in Hepatology
von Felden, J., Craig, A. J., & Villanueva, A. (2019) · Clinical Liver Disease · doi:10.1002/cld.805 · Cited by 4
Self-citationYao, W., Li, X., Jia, Z., Gu, C., Jin, Z., Wang, J., Yuan, B., & Yang, J. (2021) · BioMed Research International · doi:10.1155/2021/1466255 · Cited by 4
A High Epigenetic Risk Score Shapes the Non-Inflamed Tumor Microenvironment in Breast Cancer
Zhang, D., Wang, Y., & Yang, Q. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.675198 · Cited by 4
Kumar‐Sinha, C., & Sahai, V. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.7097 · Cited by 4
Brown, Z. J., Gregory, S., Hewitt, D. B., Iacono, S. A., Choe, J. K., Labiner, H. E., & Pawlik, T. M. (2022) · Surgical Oncology · doi:10.1016/j.suronc.2022.101748 · Cited by 4
A signature-based classification of lung adenocarcinoma that stratifies tumor immunity
Zhang, X., Jiang, D., Li, S., Zhang, X., Zheng, W., & Cheng, B. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1023833 · Cited by 4
Zhu, J., Zheng, Y., Liu, Y., Chen, M., Liu, Y., & Li, J. (2023) · Medicine · doi:10.1097/md.0000000000032707 · Cited by 4
Zeng, F., Xu, Z., & Zhuang, P. (2023) · Medicine · doi:10.1097/md.0000000000034826 · Cited by 4
Predictive Panel for Immunotherapy in Low-Grade Glioma
Lv, Q., Zhang, Z., Fu, H., Li, D., Liu, Y., Sun, Y., & Wu, M. (2024) · World Neurosurgery · doi:10.1016/j.wneu.2024.01.039 · Cited by 4
Identification and Validation of an Immune-related Prognostic Signature for Hepatocellular Carcinoma
Xia, X., Tang, P., Liu, H., & Li, Y. (2021) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00017 · Cited by 4
Wu, M.-Y., Wang, C., Chang, Y.-C., Yu, C., Sung, W., Chen, C., & Tsai, M. (2022) · Medicina · doi:10.3390/medicina58060798 · Cited by 4
Hepatocellular Carcinoma: A Review
Gupta, T. (2020) · Journal of Renal and Hepatic Disorders · doi:10.15586/jrenhep.v4i2.84 · Cited by 5
Díaz, A., & Forner, A. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.017 · Cited by 4
Is There an Impact of Locoregional Therapy on Immune Response Modulation in HCC?
Kennedy, P., Marron, T. U., & Taouli, B. A. (2022) · Radiology · doi:10.1148/radiol.211801 · Cited by 4
Imaging for better responses to immunotherapy in hepatocellular carcinoma
Lindblad, K. E., & Lujambio, A. (2022) · Hepatology · doi:10.1002/hep.32627 · Cited by 4
MATE, R. T., Chivate, A. N., Jadhav, N. R., & Chivate, N. D. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i4.53730 · Cited by 3
Qiu, Y., Zhang, H., Yu, X., Pan, J., Xiao, D., Miao, H., Wang, R., Shen, N., Pu, P., Zhou, Y. ‐., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14693-w · Cited by 3
Zhang, R., Li, M., Lu, S., Wang, A., & Zhang, S. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1613596 · Cited by 3
Pioneering precision: The evolution of immunotherapy for hepatocellular carcinoma
Foerster, F., Wiesmann, L., Bark, P., & Galle, P. R. (2025) · Hepatology · doi:10.1097/hep.0000000000001554 · Cited by 3
Xie, W., Sun, L., Fu, Y., Liu, Y., Wang, J., & Liu, L. (2025) · Academic Radiology · doi:10.1016/j.acra.2025.10.048 · Cited by 3
Yoo, S. H., Nahm, J. H., Chang, H. Y., Lee, J. I., Lim, J. H., & Lee, H. W. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020502 · Cited by 3
Pan, Y., Zeng, C., He, Y. L., Chang, R., Wu, J., Yuan, C., Li, H., Su, C., Han, M., Li, P., et al. (2026) · Nature Communications · doi:10.1038/s41467-025-68156-8 · Cited by 3
Adán-Villaescusa, E., Castelló-Uribe, B., Uriarte, I., Santamaría, E., Barbero, R., Belzunce, M., López-Pascual, A., Latasa, M. U., Elurbide, J., Valbuena-Goiricelaya, E., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102717 · Cited by 3
Self-citationZhang, Y., Sekar, K., Phua, C. Z. J., Yap, C. K., Shuen, T. W. H., Kaya, N. A., Liu, M. J., Lu, B., Tan, C. Y. L., Chong, S. L., et al. (2026) · Gut · doi:10.1136/gutjnl-2026-338227 · Cited by 3
Zhou, C., Li, M., Ren, Y., Miao, F., Wang, Y., Wu, T., Gou, X., & Li, W. (2024) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03295-0 · Cited by 3
Zhang, W., Song, L.-N., You, Y.-F., Qi, F.-N., Cui, X.-H., Yi, M., Zhu, G., Chang, R., & Zhang, H. (2024) · Artificial Intelligence in Gastroenterology · doi:10.35712/aig.v5.i1.90096 · Cited by 3
Mariussi, M., Ruelas, M. G., Lima, L., Leite, F. F., Cunha, M. J. S., Valle, L. G. M., Affonso, B. B., Galastri, F. L., Usón, P. L. S., Yamaga, L. Y. I., et al. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09139-z · Cited by 3
Immunotherapy in hepatocellular cancer
Fountzilas, C. K., Evans, R., Alaklabi, S., & Iyer, R. V. (2021) · Advances in cancer research · doi:10.1016/bs.acr.2020.12.002 · Cited by 4
Fan, Y., Hou, J., Liu, X., Han, B., Meng, Y., Liu, B., Chen, F., Shang, Y., Cao, P., & Tan, K. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.668516 · Cited by 3
Pathologie des Hepatozellulären Karzinoms
Longerich, T., & Schirmacher, P. (2022) · Der Pathologe · doi:10.1007/s00292-021-01038-0 · Cited by 3
Hepatocellular Carcinoma: Aetiology and Mechanisms of Development. A Literature Review
Меньшиков, К. В., Султанбаев, А. В., Мусин, Ш. И., Rakhmatullina, I. R., Menshikovа, I. A., Abdeev, R. R., Султанбаева, Н. И., Popova, E. V., & Serebrennikov, G. A. (2022) · Creative Surgery and Oncology · doi:10.24060/2076-3093-2022-12-2-139-150 · Cited by 4
Zhou, J. Y., Eder, D., Weber, F., Heumann, P., Kronenberg, K., Werner, J. M., Geissler, E. K., Schlitt, H. J., Hutchinson, J. A., & Bitterer, F. (2023) · Frontiers in Transplantation · doi:10.3389/frtra.2023.1211916 · Cited by 3
Lominadze, Z., Shaik, M. R., Choi, D., Zaffar, D., Mishra, L., & Shetty, K. (2023) · Cancer Journal · doi:10.1097/ppo.0000000000000682 · Cited by 2
Pulakuntla, S., Syed, K., & Reddy, V. D. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb46010009 · Cited by 3
Missale, G., & Cariani, E. (2018) · Hepatoma Research · doi:10.20517/2394-5079.2018.72 · Cited by 3
Cammarota, A., Zanuso, V., D’Alessio, A., Pressiani, T., Bozzarelli, S., Personeni, N., & Rimassa, L. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2042253 · Cited by 4
Brown, Z. J., & Greten, T. F. (2019) · Molecular and translational medicine · doi:10.1007/978-3-030-21540-8_12 · Cited by 3
Tian, Z., Yang, Z., Jin, M., Ding, R., Wang, Y., Chai, Y., Wu, J., Yang, M., & Zhao, W. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05173-4 · Cited by 3
Metadata
- Authors
- Sia, D., Jiao, Y., Martinez-Quetglas, I., Kuchuk, O., Villacorta-Martin, C., Castro de Moura, M., Putra, J., Camprecios, G., Bassaganyas, L., Akers, N., Losic, B., Waxman, S., Thung, S. N., Mazzaferro, V., Esteller, M., Friedman, S. L., Schwartz, M., Villanueva, A., & Llovet, J. M.
- Affiliations
- Tisch Cancer Institute (US)
- Hospital Clínic de Barcelona (ES)
- University of Milan (IT)
- Institució Catalana de Recerca i Estudis Avançats (ES)
- Corresponding author
- Llovet, Josep M.
- ORCID
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2017-09
- Volume
- 153
- Issue
- 3
- Pages
- 812-826
- ISSN
- 0016-5085 (ISSN-L)
- PMC
- PMC12166766
- OpenAlex
- W2626033245
- Cited by
- 976
- References
- 46
- Citations by year
- 2026: 65 · 2025: 82 · 2024: 124 · 2023: 136 · 2022: 155 · 2021: 188 · 2020: 104 · 2019: 72 · 2018: 41 · 2017: 9
- FWCI
- 27.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Gastroenterology (acceptedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (acceptedVersion, cc-by-nc-nd)
- Funders
- Tisch Cancer Institute (P30 CA196521)
- US Department of Defense (CA150272P3)
- European Commission Framework Program 7 (259744)
- Horizon 2020 Program (667273–2)
- Asociación Española Contra el Cáncer
- Samuel Waxman Cancer Research Foundation
- Spanish National Health Institute (SAF2013–41027)
- Grup de Recerca Consolidat–Recerca Translacional en Oncologia Hepàtica
- AGAUR (SGR 1162)
- European Commission HEPCAR
- Onlus Prometeo
- Hepato-Oncology Research Project
- Istituto Nazionale Tumori
- National Cancer Institute
- IRCCS Foundation
- Juan de la Cierva Fellowship
- Associazione Italiana per la Ricerca sul Cancro
- Italian Ministry of Health
- National Institutes of Health (R01DK56621)
- American Association
- Liver Diseases Foundation Alan Hofmann Clinical and Translational Award
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, tumor immune microenvironment, immune cell infiltration, PD-1, T cell exhaustion, TGF-β1, chromosomal abnormalities, cancer mutations, tumor-infiltrating immune cells, immune checkpoint inhibitors, tumor subtypes, gene expression profiling, non-negative matrix factorization, tides
- MeSH terms
- Aged, Female, Carcinoma, Hepatocellular, Humans, Immune Tolerance, Immunohistochemistry, Liver Neoplasms, Male, Middle Aged, Mutation, Signal Transduction, Gene Expression Regulation, Neoplastic, Immunophenotyping, Lymphocytes, Tumor-Infiltrating, DNA Methylation, beta Catenin, Transforming Growth Factor beta1, Adaptive Immunity, Tumor Microenvironment, Transcriptome, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
